Autopsy report · NCT00003512

Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“No participants enrolled”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 2
Sponsor: Burzynski Research Institute
Sponsor type: University, hospital or other
Conditions: Waldenstrom Macroglobulinemia
Interventions: Antineoplaston therapy (Atengenal + Astugenal)
Participants: 0
Sites: 1
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.